Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan
· Delayed Price · Currency is TWD 75.60
-0.40 (-0.53%)
Apr 29, 2026, 1:30 PM CST
Handa Pharmaceuticals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 749.77 | 472.74 | 726.89 | -40.01 | -247.67 | Upgrade
|
| Depreciation & Amortization | 163.83 | 10.16 | 12.15 | 14.82 | 16.49 | Upgrade
|
| Other Amortization | 0.31 | 0.27 | 0.3 | 0.36 | 18.67 | Upgrade
|
| Loss (Gain) From Sale of Assets | -12.84 | 0.19 | -4.61 | 0 | -0.02 | Upgrade
|
| Loss (Gain) on Equity Investments | -0.29 | 1.81 | -2.37 | - | - | Upgrade
|
| Stock-Based Compensation | 16.39 | 22.39 | 8.47 | 0.11 | 0.26 | Upgrade
|
| Other Operating Activities | -21.13 | -189.23 | 51.87 | -5.55 | -13.62 | Upgrade
|
| Change in Accounts Receivable | -762.56 | 207.08 | -226.18 | -140.58 | 13.41 | Upgrade
|
| Change in Inventory | 39.22 | - | - | 10.11 | - | Upgrade
|
| Change in Accounts Payable | 47.04 | 6.57 | 8.34 | 5.1 | -8.26 | Upgrade
|
| Change in Other Net Operating Assets | 23.9 | -34.38 | 93.51 | -55.93 | 41.51 | Upgrade
|
| Operating Cash Flow | 243.63 | 497.6 | 668.36 | -211.57 | -179.24 | Upgrade
|
| Operating Cash Flow Growth | -51.04% | -25.55% | - | - | - | Upgrade
|
| Capital Expenditures | -16.92 | -7.77 | -0.94 | -0.64 | -5.58 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0 | - | 0 | 0.03 | Upgrade
|
| Cash Acquisitions | -155.9 | -819.63 | - | - | - | Upgrade
|
| Divestitures | - | - | -10.97 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.17 | - | - | -0.12 | -1.57 | Upgrade
|
| Investment in Securities | -674.86 | 431.12 | -1,653 | 30.71 | 3.98 | Upgrade
|
| Other Investing Activities | - | -0.65 | - | -0.45 | 0.23 | Upgrade
|
| Investing Cash Flow | -847.84 | -396.92 | -1,665 | 29.5 | -2.91 | Upgrade
|
| Long-Term Debt Repaid | -13.26 | -6.07 | -7.17 | -7.19 | -7.77 | Upgrade
|
| Total Debt Repaid | -13.26 | -6.07 | -7.17 | -7.19 | -7.77 | Upgrade
|
| Net Debt Issued (Repaid) | -13.26 | -6.07 | -7.17 | -7.19 | -7.77 | Upgrade
|
| Issuance of Common Stock | 2,102 | 3.12 | 1,313 | 320.83 | 170.68 | Upgrade
|
| Repurchase of Common Stock | -57.88 | -56.52 | - | - | - | Upgrade
|
| Common Dividends Paid | -236.3 | -141.09 | - | - | - | Upgrade
|
| Other Financing Activities | -3 | - | - | - | - | Upgrade
|
| Financing Cash Flow | 1,792 | -200.55 | 1,306 | 313.65 | 162.91 | Upgrade
|
| Foreign Exchange Rate Adjustments | 22.39 | 30.2 | -8.34 | -28.97 | 2.44 | Upgrade
|
| Net Cash Flow | 1,210 | -69.67 | 301.13 | 102.6 | -16.81 | Upgrade
|
| Free Cash Flow | 226.72 | 489.84 | 667.42 | -212.21 | -184.82 | Upgrade
|
| Free Cash Flow Growth | -53.72% | -26.61% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 13.11% | 58.97% | 60.33% | -107.35% | -632.19% | Upgrade
|
| Free Cash Flow Per Share | 1.46 | 3.47 | 4.95 | -1.69 | -1.57 | Upgrade
|
| Cash Interest Paid | 1.04 | 0.49 | 0.22 | 0.28 | 0.23 | Upgrade
|
| Cash Income Tax Paid | 191.19 | 197.46 | 7.78 | 2.42 | 0.45 | Upgrade
|
| Levered Free Cash Flow | 287.3 | 438.42 | 450.86 | -224.91 | -74.36 | Upgrade
|
| Unlevered Free Cash Flow | 287.95 | 438.73 | 450.99 | -224.74 | -74.21 | Upgrade
|
| Change in Working Capital | -652.4 | 179.27 | -124.33 | -181.31 | 46.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.